<DOC>
	<DOCNO>NCT02844179</DOCNO>
	<brief_summary>This research study intend determine initial safety tolerability single oral dos drug ( + ) -alpha-dihydrotetrabenaxine ( HTBZ ) normal volunteer . HTBZ believe active ingredient FDA-approved drug tetrabenazine ( TBZ , brand name Xenazine ) , prescribe treatment involuntary movement patient Huntington 's chorea . TBZ mixture closely-related compound ( isomer ) readily metabolize ( convert ) human body HTBZ related isomer . Investigators believe HTBZ , drug study research , active ingredient TBZ . The present study confirm safety tolerability HTBZ investigate expect effect brain site target TBZ therapy .</brief_summary>
	<brief_title>( + ) -Alpha-Dihydrotetrabenazine Phase I</brief_title>
	<detailed_description />
	<criteria>able provide inform consent pregnant lactate female subject Subjects take medication interfere VMAT2 ( ex amphetamine ) History significant neurologic psychiatric condition Significant active medical condition Alcohol illicit substance use dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>